Starboard Value · activist-deck
Bristol-Myers Squibb Company (BMY)
197 pages · 0 arc beats · 2 loops
Bristol-Myers Squibb Company (BMY)
Starboard Value · 2019-03 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
1102030405060708090100110120130140150160170180190197
Deck intelligence map
1 coverage by narrative range · generated from this deck JSON
Narrative range 197 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Whole deck 197 slides 100% 197/197 slides 100% 197/197 slides · 1525 hits — 0/197 slides
8.1% 16/197 slides · 19 hits 80.2% 158/197 slides · 160 hits — 0/197 slides
5.1% 10/197 slides Slide inventory
197 every slide · same image gating as the playbook
01
Includes a quote from former BMS CEO Jim Cornelius to frame the strategic critique.front_matter
05
This is a classic activist 'thesis' slide, setting the stage for the rest of the deck.frame_problem
07
Uses a green/red color coding to contrast positive attributes of the status quo against negative attributes of the proposed deal.compare_peers
08
Uses quotes from historical documents to establish the 'String of Pearls' strategy as a long-standing corporate policy.expose_contradiction
09
Uses a visual equation (Historical Acquisitions + Internal R&D = Success) vs (Celgene Acquisition = High Risk/Patent Cliff) to frame the contradiction.expose_contradiction
10
Uses a combination of a performance table, a bar chart for margins, and a time-series line chart for P/E multiples to argue against management's M&A capability.expose_gap
11
The slide uses a '???' placeholder for the most recent deal to highlight uncertainty or impending failure.preempt_rebuttal
12
The slide uses a red-highlighted row for the most recent deal (Celgene/BMS) to emphasize the '???' performance, implying future failure.preempt_rebuttal
13
Uses a red/green bar chart to visualize performance vs index; highlights Celgene/BMS deal with question marks.preempt_rebuttal
14
The slide uses a bar chart to compare the peer average P/E multiple against the BMY acquisition price for Celgene, followed by a callout box highlighting the paexpose_contradiction
15
Uses a bar chart to contrast peer average P/E with the implied acquisition P/E for Celgene.expose_contradiction
16
Uses a bar chart to compare revenue concentration of historical patent cliffs and a stacked area chart to visualize the revenue decline of Celgene's portfolio.expose_contradiction
17
Uses red callout boxes to highlight specific underperformance percentages and a green callout for activist intervention timing.expose_contradiction
18
The slide uses a screenshot of a press release to establish credibility and provide evidence of shareholder dissent.cite_precedent
19
Uses a logical breakdown to expose a flaw in management's acquisition accounting.expose_contradiction
20
Uses a stacked bar chart comparison to illustrate the shift in valuation components.expose_contradiction
21
The slide uses a red dashed callout box to emphasize the negative implications of the management's aggressive assumptions.expose_contradiction
22
Uses red arrows for misses and green arrows for beats to visually reinforce the thesis.expose_contradiction
23
The slide uses a table to detail specific clinical and commercial risks for five products, followed by a callout regarding unidentified earlier-stage products.diagnose_problem
Open slide detailLoop · Aha Moment
24
Uses a timeline visualization to highlight the gap between historical performance and future projections.expose_contradiction
Open slide detailLoop · Aha Moment
25
Uses color-coding (red/yellow/green) to categorize product status.expose_contradiction
Open slide detailLoop · Aha Moment
26
Uses a table to show product failures/delays and a timeline to visualize the unrealistic launch cadence required.expose_contradiction
27
This is a classic 'preempt_rebuttal' slide used by activist investors to undermine management's deal rationale.preempt_rebuttal
28
The chart uses a scatter-plot style with a trend line to show the relationship between 2028 revenue and NPV.quantify_opportunity
29
Uses a rhetorical question as a callout to emphasize the absurdity of the timeline.expose_contradiction
30
This is a classic activist investor 'thesis' slide, focusing on valuation gaps and management incompetence.diagnose_problem
31
The slide uses a combination of a peer comparison bar chart and a forward-looking FCF projection to justify the thesis.quantify_opportunity
32
Uses a peer benchmark chart to highlight the margin gap between BMY and its peers.diagnose_problem
36
The slide uses a quote from a 2008 tender offer to define the 'String of Pearls' strategy and contrasts it with a 2016 conference slide showing recent partnershsummarize
37
The slide uses a grid of pull-quotes to establish credibility and market sentiment.cite_precedent
38
The slide highlights the market's positive reaction to the 'String of Pearls' strategy prior to the CEO transition.compare_peers
39
This slide is used by an activist investor to frame the CEO transition as a point of investor concern.introduce_nominees
40
The slide uses a 'villain' narrative (Caforio) to frame poor stock performance against specific clinical milestones.expose_contradiction
41
The slide uses a stock chart to visualize the financial impact of a specific corporate failure.name_villain
42
The slide uses a narrative structure to explain the scientific context before pivoting to the clinical trial failure.diagnose_problem
43
Uses a side-by-side comparison structure to highlight strategic failure vs success.expose_contradiction
44
The slide uses external quotes to build a narrative of management hubris and poor strategic decision-making.expose_contradiction
46
The slide uses a red-pill visual motif for the trial names to emphasize failure.expose_contradiction
47
Uses a combination of quarterly revenue charts and a qualitative quote to explain the market shift.expose_contradiction
48
Includes a screenshot of a BMS slide and a bar chart of sales estimates.summarize
49
The slide uses a red highlight for BMY to emphasize its outlier status in both charts.compare_peers
50
Includes a summary table and three line charts showing stock performance relative to S&P 500, DRG, and S-4 peers.compare_peers
51
The slide uses a red dashed line to visually emphasize the decline of Bristol-Myers' P/E ratio relative to its historical peak.expose_gap
52
The slide uses a red dashed line to emphasize the downward trend from the peak.expose_contradiction
53
The slide uses a red dashed box to highlight the specific transaction being criticized.cite_precedent
54
Uses a red box to highlight the Celgene/BMS deal as a current/future concern.preempt_rebuttal
55
Uses a bar chart to compare revenue concentration of blockbuster drugs and a stacked area chart to visualize the revenue decline of Celgene's portfolio.expose_contradiction
57
Uses a bar chart to illustrate the valuation gap and potential for multiple compression.show_valuation_bridge
58
Uses CEO/CFO quotes as evidence to support the thesis that patent cliffs drive M&A activity.preempt_rebuttal
59
The slide uses red callout boxes to emphasize specific points of underperformance and a green callout to mark an activist intervention.compare_peers
62
The slide uses a line chart to contrast the revenue decay curves of small molecules vs biologics to argue that Celgene's portfolio is structurally vulnerable.expose_contradiction
63
The chart uses a waterfall-style visualization to show cumulative revenue loss over time.diagnose_problem
64
The slide uses a red trend line and callouts to highlight the frequency and magnitude of price hikes.expose_contradiction
65
Uses screenshots of news articles and government speech excerpts to build a case against the company's pricing strategy.expose_contradiction
67
The slide uses a combination of a quote/excerpt and a data table to build a case against the company's business practices.expose_contradiction
68
The slide uses a process-style arrow to show the transition from a list of challengers to specific settlement outcomes.preempt_rebuttal
69
The slide uses a stacked area chart to visualize the 'cliff' effect of patent expirations.expose_contradiction
71
Uses a screenshot of a Bristol-Myers slide to expose the contradiction.expose_contradiction
Open slide detailLoop · Iceberg
72
The slide uses a stacked bar chart to visualize the components of the deal value and a bulleted list to detail the specific DCF assumptions.analyze_data
Open slide detailLoop · Iceberg
73
The slide uses a stacked area chart to visualize the revenue cliff for Celgene's portfolio.expose_contradiction
Open slide detailLoop · Iceberg
74
Includes a waterfall-style bridge diagram showing the components of the BMY deal value.show_valuation_bridge
Open slide detailLoop · Iceberg
75
Includes a table of DCF projections and a stacked bar chart illustrating the deal value components.show_valuation_bridge
Open slide detailLoop · Iceberg
76
Uses a table to highlight a logical impossibility (synergies > costs) to challenge management's valuation assumptions.expose_contradiction
Open slide detailLoop · Iceberg
77
Uses a reductio ad absurdum argument to challenge the company's valuation narrative.expose_contradiction
Open slide detailLoop · Iceberg
78
The slide uses a DCF model to cap the potential synergy value, explicitly noting that 100% cost elimination is unrealistic.show_valuation_bridge
79
Includes a waterfall-style bridge diagram comparing the $62B calculated value to the $75B management claim.show_valuation_bridge
80
The slide uses a waterfall-style logic to bridge the total synergy value into two distinct buckets (marketed vs pipeline).show_valuation_bridge
81
Uses a waterfall-style bridge to reallocate synergies and expose the true cost of the pipeline.expose_contradiction
83
Uses a table to derive implied pipeline revenue and a callout box to highlight the specific 2028 assumption.expose_contradiction
84
The slide uses a callout box to emphasize the short due diligence period relative to the size of the revenue bet.expose_contradiction
85
The slide uses a bar chart with a red arrow to highlight the 59% delta between the two figures.expose_contradiction
86
The slide uses a series of small bar charts (indexed to 100) with arrows indicating direction of variance (red for negative, green for positive).expose_contradiction
87
Uses a combination of a 10-K excerpt and a pie chart to highlight the discrepancy between industry reality and management's valuation assumptions.expose_contradiction
88
The slide uses a red dashed circle to highlight the 'Average Expected Revenue Per Product' metric as the key point of contention.expose_contradiction
89
Uses a timeline to visualize the gap between historical performance (3 launches in 15 years) and projected performance (10 launches in 8 years).expose_contradiction
90
Uses a before-after framing to highlight the shift from non-specific bullishness to specific product hype.expose_contradiction
91
The slide uses a before-and-after comparison to highlight management inconsistency.expose_contradiction
92
The slide uses a chronological sequence of screenshots to demonstrate the degradation of management's pipeline transparency.expose_contradiction
93
Uses a 'before-after' style critique of management guidance vs reality.expose_contradiction
94
The slide uses color-coding (red, orange, green) to categorize drug status, effectively visualizing the failure of management's previous projections.expose_contradiction
95
Uses a side-by-side comparison table to highlight the gap between internal management hype and external analyst skepticism.expose_contradiction
96
Uses a combination of direct quotes and a bar chart to demonstrate the gap between management guidance and reality.expose_contradiction
97
The slide uses a waterfall-style annotation to highlight the $30 billion loss in shareholder value.expose_contradiction
98
The slide uses a table to systematically dismantle the credibility of management's revenue projections for the Celgene acquisition.diagnose_problem
99
The slide uses a screenshot of a Celgene presentation to highlight the company's 'blockbuster' claims, which the activist then challenges.expose_contradiction
100
Uses a combination of a bar chart and pull-quotes to highlight the gap between management's 'blockbuster' narrative and analyst reality.expose_contradiction
101
Uses a Q&A excerpt from a 2019 conference to frame management's complacency.expose_contradiction
102
Uses screenshots of news articles to provide evidence of the company's past poor capital allocation and clinical failure.expose_contradiction
103
Uses news clippings as evidence to build a narrative of poor capital allocation or high-risk acquisition strategy.expose_contradiction
104
Uses a direct excerpt from a 10-K filing to establish the liability and a bar chart to establish the revenue expectation.expose_contradiction
105
Uses CEO and President quotes to establish the baseline of management's public optimism.expose_contradiction
106
Uses a before-after framing to contrast management's pre-RTF optimism with post-RTF deflection.expose_contradiction
107
Uses a combination of stock price performance and revenue estimate charts to highlight management failure.expose_contradiction
108
The slide uses a combination of a logo grid for competitors and a series of pull-quotes to frame the product as facing an uphill battle.name_villain
109
The slide uses a 'CEO quote contradiction' or 'authority citation' approach by leveraging Arena's own presentation materials to build the activist's case.compare_peers
110
Uses a screenshot of a research report with a callout box to emphasize the contradiction.expose_contradiction
111
The slide uses a 'Competitive Landscape' map to visualize the density of ongoing research, contrasting the limited number of approved products with the high volcompare_peers
112
Uses CEO quotes to validate the claim of manufacturing difficulty.diagnose_problem
113
Uses screenshots of news articles as evidence of public and regulatory sentiment.preempt_rebuttal
114
Uses a screenshot of a Celgene investor presentation to highlight the $3B peak sales claim.expose_contradiction
115
The slide uses a 'yellow flags' metaphor to frame the management team as untrustworthy.name_villain
116
Uses a timeline framework to highlight management's shifting narrative.expose_contradiction
117
The slide uses a timeline to frame the late entry as a strategic failure or disadvantage.diagnose_problem
118
Uses a combination of a line chart and qualitative quotes to build a bearish case on CAR-T commercial viability.expose_contradiction
119
Uses a combination of a bar chart to show analyst variance and pull-quotes to show expert skepticism.preempt_rebuttal
121
The slide highlights the long-term cash burn associated with the Celgene acquisition pipeline.diagnose_problem
122
The chart uses a line graph to show NPV crossing the zero threshold at $15B revenue.show_valuation_bridge
123
The slide uses a numbered list to structure the argument, focusing on product failure, sales underperformance, and generic competition risks.diagnose_problem
124
Uses a waterfall-style bridge to decompose revenue expectations and contrast them with the reality of product development risk.expose_contradiction
125
Uses a timeline to contrast historical launch frequency with projected future requirements.preempt_rebuttal
126
The slide uses color-coding (red, yellow, green) to categorize drug status, effectively acting as a visual 'stoplight' framework for management credibility.expose_contradiction
127
The chart uses a waterfall-like logic to show value destruction based on the number of product failures.preempt_rebuttal
128
Uses a waterfall-style bridge to illustrate the delta between management's case and analyst consensus.preempt_rebuttal
129
Uses a Gordon Growth Method for terminal value calculation.show_valuation_bridge
130
Uses a table to decompose the implied assumptions of Bristol-Myers' pipeline valuation.expose_contradiction
131
Uses a waterfall-style logic to bridge from base case to adjusted case, highlighting value destruction.show_valuation_bridge
132
The slide uses a series of small bar charts with arrows to indicate whether actual performance exceeded (green) or fell short (red) of consensus estimates.preempt_rebuttal
133
Uses a waterfall-bridge style chart to illustrate the gap between base case and historical performance.show_valuation_bridge
134
Uses a process-flow style layout to show the progression from generic challenges to specific settlement outcomes.expose_gap
135
Includes a waterfall-style bridge diagram showing the components of BMY management's valuation view.show_valuation_bridge
136
This is a classic 'preempt rebuttal' slide used by activist investors to undermine management's optimistic projections.preempt_rebuttal
137
This is a classic activist investor thesis slide challenging an M&A deal.frame_problem
138
Uses red dashed boxes and arrows to highlight the specific EPS comparison between the two scenarios.expose_contradiction
140
Uses a rhetorical question as a callout to highlight the absurdity of the short diligence timeline.expose_contradiction
141
Uses a calendar visualization to highlight the compressed timeline between data room access and deal approval.expose_contradiction
142
Uses a specific case study (Bristol-Myers/Celgene) to highlight a contradiction in standard M&A deal dynamics.expose_contradiction
143
Uses a timeline framework to contrast the urgency of the acquirer against the target's caution.expose_contradiction
144
Uses a 'contradiction' framework to contrast the Committee's charter requirements with the actual timeline of the Celgene acquisition.expose_contradiction
145
Uses a combination of direct quotes and regulatory filing excerpts to build a case of management negligence.expose_contradiction
146
Uses a timeline-style list to demonstrate long-standing market sentiment.preempt_rebuttal
147
Uses a line chart overlaid with callouts to correlate specific events with stock price movements.expose_contradiction
148
The slide attempts to frame the Celgene merger as a 'poison pill' or entrenchment strategy rather than a strategic business decision.expose_contradiction
149
The slide uses a 'before-after' or 'contradiction' framing to suggest management was previously evasive about M&A interest.expose_contradiction
150
Uses a dual-chart layout to illustrate market cap scale and revenue concentration risk.preempt_rebuttal
152
Uses a before-and-after comparison of Amgen's stated goals vs. actual outcomes to build credibility.cite_precedent
153
The slide uses a precedent (Amgen) to argue for a specific operational strategy at the target company (Bristol-Myers).compare_peers
154
The slide uses a 'precedent' framework to validate the activist's thesis by showing successful execution by a peer.cite_precedent
155
The slide uses a green arrow to visually quantify the 63% outperformance gap between Amgen and BMY.cite_precedent
156
The slide uses S-4 filing data to support the activist's argument that the company is fundamentally strong, likely to contrast with a critique of management's esummarize
157
The slide uses bar charts with trend lines to highlight growth trajectories for two key products.analyze_data
159
This slide is likely used to set up a future contradiction by establishing the company's own bullish narrative.expose_contradiction
160
The slide uses a structured table to demonstrate a pipeline of growth opportunities.quantify_opportunity
162
Uses CEO/CFO quotes to frame management's narrative against the actual performance data.expose_contradiction
163
Uses a combination of a peer net cash comparison and a 5-year FCF projection to justify the thesis.quantify_opportunity
164
Uses S-4 filing data to contrast internal vs external expectations.expose_contradiction
165
The chart includes a hypothetical 'PF BMY - Identified Opportunities' bar to illustrate the potential margin expansion.expose_gap
167
The slide uses a waterfall bridge to show how a 36% margin can reach 45% through operational efficiencies.quantify_opportunity
168
The chart includes a hypothetical 'PF BMY - Identified Opportunities' bar to illustrate the target margin.compare_peers
169
The slide uses a map to visualize the geographic dispersion of facilities, supporting the argument for consolidation.diagnose_problem
171
The slide uses a process flow diagram to illustrate the sequential steps in biologics manufacturing, paired with a timeline table.establish_context
172
The slide uses a process flow diagram to highlight the specific stage (Cell Culture) targeted for optimization.propose_solution
173
Includes a process flow diagram illustrating stages 1-5 of biologics manufacturing.present_framework
174
The slide uses a specific manufacturing process flow (bioprocessing) to argue for operational efficiency gains.propose_solution
175
Uses a numbered list for strategies and a callout box for expert estimates.propose_solution
176
The chart includes a specific 'PF BMY - Identified Opportunities' bar to illustrate the potential target.compare_peers
177
Uses red bars for the subject company and blue bars for the peer benchmark to emphasize the gap.compare_peers
178
Uses red-to-blue color coding to emphasize the gap between the subject company and the benchmark.compare_peers
179
Includes a quote from an Amgen executive to support the proposed strategy.propose_solution
180
Includes a quote from a former executive to support the argument for organizational streamlining.compare_peers
181
The slide uses a red bar for the subject company (BMY) to contrast with blue peer bars.compare_peers
182
The slide uses a comparison frame to highlight BMY's inefficiency relative to PFE.compare_peers
183
The slide uses a red bar for the target company (BMY) to highlight underperformance.compare_peers
184
The slide uses a bar chart to highlight BMY's outlier status compared to the peer average.compare_peers
185
The slide uses a 'Total Nearer-Term Expected Product Launches' calculation to highlight the lack of pipeline depth.expose_contradiction
187
Uses a combination of qualitative testimonials and quantitative benchmarking (Amgen's 3% improvement) to argue for operational change.expose_contradiction
189
This is a classic activist investor 'vote no' slide, highlighting valuation discrepancies and execution risk.diagnose_problem
190
The slide uses a red callout box to emphasize the negative implications of the management's aggressive assumptions.expose_contradiction
191
Uses a timeline visual to contrast historical performance (3 launches in 15 years) with projected performance (10 launches in 8 years).expose_contradiction
192
The chart uses a line graph with red dots representing failure scenarios and a blue dot for the base case.diagnose_problem
193
Uses a bar chart to visualize the margin gap between BMY and its peers, highlighting a 'PF BMY - Identified Opportunities' bar to show potential improvement.propose_solution
194
The slide uses a combination of a categorical table for market share and two bar charts for financial projections.summarize
195
Uses a combination of a peer net cash comparison and a 5-year FCF projection to justify the thesis.quantify_opportunity
196
The slide uses a waterfall bridge to visualize the path from current 36% EBITDA margin to a 45% pro forma margin.propose_solution
197
The slide uses a clear 'us vs. them' framing, positioning the proposed acquisition as high-risk and value-destructive compared to the standalone alternative.closing_ask